Meeting
2019 ASCO Annual Meeting
A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.
Authors
Kim Anna Reiss
University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
Kim Anna Reiss , Rosemarie Mick , Mark H. O'Hara , Ursina R. Teitelbaum , Thomas Benjamin Karasic , Charles John Schneider , Peter J. O'Dwyer , Danielle Karlson , Stacy Cowden , Mary Jane Fuhrer , Erica L. Carpenter , Austin A Pantel , Mehran Makvandi , David A. Mankoff , Katharine Nathanson , Kara Noelle Maxwell , Gregory Lawrence Beatty , Susan M. Domchek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT 03404960
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4161)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4161
Abstract #
TPS4161
Poster Bd #
256a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).
First Author: Kim Anna Reiss
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
First Author: Sylvie Lorenzen
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney